An Exploratory, Multicentre, Double-blind, Double-dummy, Randomised, Parallel-group, Controlled Phase III Study to Evaluate the Safety and Tolerability of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) in Treatment of Elderly Subjects with Alzheimers Disease with Symptoms of Psychosis and/or Agitation Compared to Seroquel Immediate Release Formulation.

Study identifier:5077IL/0115

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Exploratory, Multicentre, Double-blind, Double-dummy, Randomised, Parallel-group, Controlled Phase III Study to Evaluate the Safety and Tolerability of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) in Treatment of Elderly Subjects with Alzheimers Disease with Symptoms of Psychosis and/or Agitation Compared to Seroquel Immediate Release Formulation.

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 May 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria